Quick answer
Your prostate cancer risk group comes from four pieces of information at diagnosis: the PSA, the ISUP grade group on biopsy, the stage on digital rectal exam and the lymph nodes on imaging. In the 2026 European guideline table, the groups are low risk, favourable intermediate, unfavourable intermediate, high risk and locally advanced.1 The most serious factor always decides. The group guides the conversation about surveillance, surgery or radiotherapy, but it is only one part of the decision, and the calculator result is something to bring to your consultation.
Find your risk group
You need the PSA from before the biopsy, the biopsy report and what the urologist noted about the rectal exam. If you have had a CT or bone scan, check whether the report mentions a suspicious lymph node.
Your answers stay in your browser. Nothing is sent, stored or saved in cookies, and everything is cleared when you close the page.
The calculation follows table 4.3 of the European guideline, with a PSA of exactly 10 or 20 ng/mL counting as "between 10 and 20". If your report gives more than one grade, use the highest. If you have just received your biopsy result, the page just diagnosed with prostate cancer explains the first steps.
The four pieces of information
- PSA: your blood test result at diagnosis, in ng/mL. The cut-offs in the table are 10 and 20 ng/mL.1 The page on PSA explains the test.
- ISUP grade group: the biopsy grade, from 1 to 5. It replaced the Gleason sum with five groups: ISUP 1 is Gleason 3+3, ISUP 2 is 3+4, ISUP 3 is 4+3, ISUP 4 is Gleason 8, and ISUP 5 is Gleason 9 or 10. In a study of 20,845 men treated with surgery, the risk of the PSA coming back was 1.9 times higher with Gleason 3+4 than with 3+3, and 5.1 times higher with 4+3.3 The page on Gleason and ISUP explains the report.
- Clinical stage (cT): what the rectal exam can feel. In cT1, the tumour cannot be felt. In cT2, a tumour can be felt but is still inside the prostate. In cT3, the tumour goes through the capsule or reaches the seminal vesicles. In cT4, it is fixed to nearby structures. The guideline recommends basing cT on the rectal exam alone and reporting MRI findings separately.1
- Lymph nodes (cN): if a CT or bone scan shows suspicious lymph nodes in the pelvis, the case is cN1. That is the reference used in the European table.1 If a node showed up on a PSMA PET, bring the report to your consultation, because it also matters for the plan.
The European guideline table
This is the table the calculator uses, from the 2026 European guideline:1
| Group | Definition |
|---|---|
| Low risk | ISUP 1 and PSA below 10 ng/mL, with a tumour confined to the prostate on rectal exam (cT1-2) |
| Favourable intermediate | ISUP 2 with PSA below 10 ng/mL, or ISUP 1 with PSA between 10 and 20 ng/mL, with cT1-2 |
| Unfavourable intermediate | ISUP 2 with PSA between 10 and 20 ng/mL, or ISUP 3, with cT1-2 |
| High risk | ISUP 4 or 5, or PSA above 20 ng/mL |
| Locally advanced | Tumour outside the prostate on rectal exam (cT3 or cT4) or suspicious lymph nodes (cN1), with any ISUP grade and any PSA |
The group is set by the most serious factor. For example, ISUP 2 with a PSA of 25 ng/mL is high risk, because of the PSA. ISUP 1 with a PSA of 12 ng/mL is favourable intermediate risk. In the 2026 table, cT2a, cT2b and cT2c are grouped together, and cT2c no longer leads to high risk.
What changes in each group
- Low risk: the European guideline makes active surveillance the standard approach, with scheduled PSA tests, rectal exams, MRI and biopsies, and curative treatment if the tumour changes.2
- Intermediate risk: the guideline accepts radical prostatectomy for men with a life expectancy of more than 10 years and radiotherapy with 4 to 6 months of hormone therapy. It accepts surveillance only in carefully selected ISUP 2 cases, with less than 10% pattern 4 and PSA below 10 ng/mL, and excludes ISUP 3 and tumours with a cribriform or intraductal pattern.2 Personally, I do not recommend active surveillance for intermediate risk, including favourable intermediate risk. The page on intermediate risk covers the studies.
- High risk: the guideline recommends offering radical prostatectomy to selected patients, with extended lymph node dissection, and accepts radiotherapy with 2 to 3 years of hormone therapy.2
- Locally advanced: without suspicious lymph nodes, surgery can be offered to selected patients as part of combined treatment, and radiotherapy comes with at least 2 years of hormone therapy.2 The page on high risk explains both groups.
For intermediate and high risk, when I recommend surgery, I advise operating as soon as possible. Hormone therapy before prostatectomy is not recommended,2 and I do not use it while the patient waits for surgery. The options are compared in surgery or radiotherapy.
What the table does not show
The table puts quite different cases into the same group. In a Swedish study of 72,337 men, a five-group system, the Cambridge Prognostic Groups, predicted death from prostate cancer better than the older three-group system.4 The 2026 European guideline now splits intermediate risk into favourable and unfavourable and says this split is similar to the Cambridge groups.1
The guideline also mentions other information that improves prediction, such as a cribriform or intraductal pattern in the report and MRI findings, but these still need to be validated in more populations.1 And some things no table measures: your age, other illnesses, how your urine and erections are today and what you want to preserve. That is why the calculator tells you which group your case falls into and does not tell you which treatment to have.
My approach
At the consultation, I review the biopsy report, your PSA history, the rectal exam, the MRI and, when indicated, the PSMA PET. With that, I explain which group your case is in and what the guideline and the studies show for it.
I do not recommend active surveillance for intermediate risk, including favourable intermediate risk. When surgery is the way forward, I perform robotic radical prostatectomy and advise operating as soon as possible. If you already have a diagnosis and would like another opinion, a second opinion can be done entirely online, in English, with your tests sent in advance.
Send your case
If you have received a diagnosis and would like my opinion on your case before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.
Frequently asked questions
How do I find out my prostate cancer risk group?+
In the European guideline, the group comes from four pieces of information at diagnosis, the PSA, the ISUP grade group on biopsy, the stage on digital rectal exam (cT) and the lymph nodes on imaging (cN). The groups are low risk, favourable intermediate, unfavourable intermediate, high risk and locally advanced.1 The calculator on this page does that calculation.
What is the difference between favourable and unfavourable intermediate risk?+
In the 2026 European table, favourable means ISUP 2 with PSA below 10 ng/mL, or ISUP 1 with PSA between 10 and 20 ng/mL. Unfavourable means ISUP 2 with PSA between 10 and 20 ng/mL, or any ISUP 3. In both, the tumour is confined to the prostate on rectal exam.1
Does a cT2b or cT2c tumour change the risk group?+
In the 2026 table, no. Any tumour confined to the prostate on rectal exam counts as cT1-2, and the group is decided by the ISUP grade and the PSA. When the rectal exam shows the tumour outside the prostate (cT3 or cT4), the case becomes locally advanced.1
Does the MRI stage count in the calculator?+
The European guideline recommends basing the clinical stage on the rectal exam alone and reporting MRI findings separately, as a strong recommendation.1 That is why the calculator asks about the rectal exam. What the MRI shows, such as extension through the capsule, still matters for treatment planning and should come to your consultation.
Does low-risk prostate cancer need treatment?+
Usually not straight away. The European guideline makes active surveillance the standard approach for low-risk cancer, with scheduled PSA tests, rectal exams, MRI and biopsies, and curative treatment if the tumour changes.2
Can favourable intermediate-risk cancer be managed with active surveillance?+
The European guideline accepts surveillance in carefully selected ISUP 2 cases with little disease, such as less than 10% pattern 4 and PSA below 10 ng/mL. ISUP 3 and tumours with a cribriform or intraductal pattern are excluded.2 Personally, I do not recommend active surveillance for intermediate risk, including favourable intermediate risk.
What changes with high-risk and locally advanced cancer?+
The European guideline recommends offering radical prostatectomy to selected patients, with extended lymph node dissection, and accepts radiotherapy with 2 to 3 years of hormone therapy for high risk and at least 2 years for locally advanced disease.2 When I recommend surgery, I advise operating as soon as possible, with no hormone therapy while the patient waits.
Who can assess prostate cancer risk groups in São Paulo?+
I see men with newly diagnosed prostate cancer in São Paulo. I am Dr. Petronio Melo, a urologist and robotic surgeon, CRM-SP 157.598 and RQE 70.275, and a reference in prostate cancer. I hold a PhD from the University of São Paulo Medical School, with award-winning research on artificial intelligence in prostate cancer diagnosis, and I have performed more than 1,500 robotic and laparoscopic surgeries, more than 500 of them robotic. At the consultation, I review the biopsy, the PSA, the rectal exam and the scans and explain which group your case falls into. My office is in Vila Mariana, and the first consultation can be in person or online, in English.
References
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: classification and staging systems (table 4.3). European Association of Urology; 2026. EAU
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
- Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 2016;69(3):428-435. PubMed
- Gnanapragasam VJ, Bratt O, Muir K, et al. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Med. 2018;16(1):31. PubMed
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation5.0186 Google reviews
